Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19 Pharmaceutical Investing
Gilead Announces Clinical Hold on Studies Evaluating Injectable Lenacapavir for HIV Treatment and Prevention Due to Vial Quality Concerns Pharmaceutical Investing
Gilead and Arcus Biosciences Complete Closing of Option Exercise for Three Clinical-Stage Programs and New Research Collaboration Pharmaceutical Investing
Lobe Sciences Announces Publication of PCT Patent Application for Its Combination Therapy for mTBI and PTSD Pharmaceutical Investing
European Commission Expands Indication for Veklury for the Treatment of Adults Not on Supplemental Oxygen and Considered High Risk for COVID-19 Disease Progression Pharmaceutical Investing
Pfizer's VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate Pharmaceutical Investing
Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply Pharmaceutical Investing
BELLUS Health Closes US$200 Million Public Offering of Common Shares in Canada and the United States Pharmaceutical Investing
Bristol Myers Squibb to Report Results for Fourth Quarter 2021 on February 4, 2022 Pharmaceutical Investing
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® as Adjuvant Therapy for Certain Patients With Renal Cell Carcinoma Following Surgery Pharmaceutical Investing
Daiichi Sankyo Authorizes the First YESCARTA® CAR T-cell Therapy Treatment Site in Japan Pharmaceutical Investing
Merck and Ridgeback Announce Publication of Phase 3 Study of Molnupiravir, an Investigational Oral Antiviral COVID-19 Treatment, in the New England Journal of Medicine Pharmaceutical Investing
